Latest Reperfusion injury Stories
SEATTLE, April 19, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that research on mannan-binding lectin-associated serine protease-2 (MASP-2) has been published in the April 18, 2011 Early Online Edition of the Proceedings of the National Academy of Sciences (PNAS).
University of Cincinnati researchers have discovered a new protein that could be cardioprotective during heart attack, potentially leading to more targeted treatments for patients at risk.
PORTOLA VALLEY, Calif., Nov. 2, 2010 /PRNewswire/ -- Spectros Corporation presented new clinical results using tissue oxygen saturation with the T-Stat VLS Tissue Oximeter at the San Diego Convention Center during Anesthesiology 2010.
Liver surgery has become a safe procedure in the past years and is mainly done because of malignant tumors.
Researchers have teased out the molecular process that can shut down a marauding, often deadly immune response that kills thousands each year who suffer battlefield casualties, heart attacks, strokes, automobile accidents and oxygen deprivation.
The wider use of reperfusion therapy in patients with heart attack (AMI) can save millions of lives in Europe. Effective reperfusion therapy in an AMI patient can cut the individual risk of dying by half.
It is known that I/R induces an inflammatory response deleterious to the organ involved but also to the system as a whole. Mesenteric ischemia occurs when the veins or arteries that supply blood to the intestine are obstructed.
Adenosine Regulation with GP531 Improves the Heart's Pumping Function in Dogs with Advanced Chronic Heart Failure NEW YORK, June 3 /PRNewswire/ -- PeriCor Therapeutics, Inc.
Researchers have discovered one potential mechanism by which briefly cutting off, then restoring, blood flow to arteries prior to a heart attack lessens the damage caused, according to a study published today in the journal Cardiovascular Research.
Fibrex Medical, a biopharmaceutical company focusing on cardiovascular and inflammatory diseases, has announced positive Phase II results for FX06, a peptide for the treatment of reperfusion injury - the damage to heart muscle that results from remedial treatment following a heart attack.
- A volcanic mudflow.